// App-Quantinova.ai

9504 : Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

Researchers

Presenter

  • Ana Maria Arance

Principal Investigators

  • Luis de la Cruz-Merino

  • Teresa M. Petrella

  • Rahima Jamal

  • Lars Ny

  • Ana Carneiro

  • Alfonso Berrocal

  • Ivan Marquez-Rodas

  • Anna Spreafico

  • Victoria Atkinson

  • Fernanda Costa Svedman

  • Andrew Mant

  • Alan D. Smith

  • Ke Chen

  • Scott J. Diede

  • Clemens Krepler

  • Georgina V. Long

Medical Centers

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Centre hospitalier de l’Université de Montréal, Montréal, ON, Canada

  • University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden

  • Lund University Hospital and Lund University, Lund, Sweden

  • Hospital General Universitario, Valencia, Spain

  • Hospital General Universitario Gregorio Marañón and CIBERONC, Madrid, Spain

  • Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.

  • Princess Alexandra Hospital and University of Queensland, Brisbane, Australia

  • Karolinska University Hospital, Stockholm, Sweden

  • Eastern Health Clinical School, Monash University, Melbourne, Australia

  • Eisai Ltd., Hatfield, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ, Melanoma Institute Australia

  • University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia

Locations

  • Spain

  • Canada

  • Sweden

  • Australia

  • United Kingdom

Companies

  • Eisai Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT03776136

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved